Company: ZVRA
Filing Date: 2025-04-24
Form Type: PRRN14A
Source: 0000897069-25-000871
Chunk: 18

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: PRRN14A
Chunk 18
---
 the President of David Francis & Co., Inc., a proxy solicitation firm. From 1984 to 1988, Mr. Regan served as Vice President at Morrow & Co, Inc., a proxy solicitation firm. From 1997 to 2000 he served as an outside director and Corporate Secretary for US Wats, Inc., a Bala Cynwyd, PA based publicly held telecommunications firm until that firm was merged out of existence. Mr. Regan has also served as a Trustee of the Madison Strategic Sector Premium Fund from 2017 until it merged in 2018 into the Madison Covered Call & Equity Strategy Fund. Mr. Regan has had numerous articles published on shareholder related matters and has been a guest lecturer or speaker at NYU’s Graduate School of Business & Siena College. Mr. Regan received a Bachelor of Science from New York University in 1984. Mr. Regan has not held any position or office with the Company and, to his knowledge, none of the positions he has held or is currently holding are or were with a corporation or organization that is a parent, subsidiary, or affiliate of the Company. In concluding that Mr. Regan should serve as a director of the Company, the Proponent considered his various management roles. Mr. Regan has the organizational and leadership skills that would be useful to the Company. For these reasons, the Proponent believes Mr. Regan should serve as a director of the Company. Except as disclosed in this Proxy Statement with regards to the Proponent, as of the date of this Proxy Statement, the Nominees do not directly or indirectly own, beneficially or of record, any securities of the Company and have not entered into any transactions in securities in the Company during the past two years. Other than as stated in this Proxy Statement, there are no arrangements or understandings between the Proponent and any of the Nominees or any other person or persons pursuant to which the nomination of the Nominees described herein is to be made. None of the Nominees is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries in any material pending legal proceedings. With respect to each of the Nominees, none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the Exchange Act occurred during the past ten years. If elected, each Nominee would receive such directors’ fees as may be payable by the Company in